RayKnowChina Research Map
Shortlist

RecruitingLung cancerBreast cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors

An open trial on lung cancer and breast cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07250386, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed advanced, metastatic, or recurrent solid tumors, including non-small cell lung cancer and breast cancer.

    Inclusion criterion 2

    CEA positivity confirmed by immunohistochemistry (IHC) in tumor samples within 3 months of screening (clear membrane staining, with positivity rate ≥10%). If the IHC result is more than 3 months old, serum CEA must be above 10 ng/mL.

    Inclusion criterion 4

    For patients with malignant pleural effusion, accurate volume assessment of pleural effusion by imaging (CT or MRI) and cytological or thoracoscopic biopsy confirmation of malignant pleural effusion.

    Inclusion criterion 6

  3. ECOG performance status of 0-2.

    Inclusion criterion 7

  4. Hematology: White blood cell count >2.0×10\^9/L, neutrophils >1.0×10\^9/L, lymphocytes >0.5×10\^9/L, platelets >50×10\^9/L, hemoglobin >80 g/L.

    Inclusion criterion 11

    Renal function: Serum creatinine ≤2.0×ULN.

    Inclusion criterion 13

    Liver function: ALT and AST ≤3.0×ULN (≤5.0×ULN for those with liver tumor infiltration).

    Inclusion criterion 14

    Total bilirubin ≤2.0×ULN.

    Inclusion criterion 15

  5. At least one evaluable lesion according to RECIST 1.1, with a longest diameter of ≥10 mm for non-lymph node lesions and a shortest diameter of ≥15 mm for lymph node lesions. Malignant pleural effusion is acceptable for the chest infusion subgroup.

    Inclusion criterion 5

  6. History of or concurrent untreated malignancies within 3 years, except for basal cell carcinoma or in situ cervical cancer.

    Exclusion criterion 13

    Positive for HBsAg or HBcAb with HBV DNA levels above the normal range, HCV antibody positive with HCV RNA levels above the normal range, HIV antibody positive, or positive for syphilis.

    Exclusion criterion 14

  7. Consent to use a reliable and effective method of contraception for 1 year after CAR-T cell infusion (excluding the rhythm method).

    Inclusion criterion 18

    Pregnant or breastfeeding women.

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07250386, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Aged 18 years or older, of any gender.
  • Histologically or cytologically confirmed advanced, metastatic, or recurrent solid tumors, including non-small cell lung cancer and breast cancer.
  • Disease progression or intolerance after at least second-line standard therapy, including but not limited to surgery, chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
  • CEA positivity confirmed by immunohistochemistry (IHC) in tumor samples within 3 months of screening (clear membrane staining, with positivity rate ≥10%). If the IHC result is more than 3 months old, serum CEA must be above 10 ng/mL.
  • At least one evaluable lesion according to RECIST 1.1, with a longest diameter of ≥10 mm for non-lymph node lesions and a shortest diameter of ≥15 mm for lymph node lesions. Malignant pleural effusion is acceptable for the chest infusion subgroup.
  • For patients with malignant pleural effusion, accurate volume assessment of pleural effusion by imaging (CT or MRI) and cytological or thoracoscopic biopsy confirmation of malignant pleural effusion.
  • ECOG performance status of 0-2.
  • Life expectancy of 12 weeks or more.
  • No serious psychiatric disorders.
  • The following organ function criteria should be met unless otherwise specified:
  • Hematology: White blood cell count >2.0×10\^9/L, neutrophils >1.0×10\^9/L, lymphocytes >0.5×10\^9/L, platelets >50×10\^9/L, hemoglobin >80 g/L.
  • Cardiac function: Echocardiography showing ejection fraction ≥50%, with no significant abnormalities on ECG.
  • Renal function: Serum creatinine ≤2.0×ULN.
  • Liver function: ALT and AST ≤3.0×ULN (≤5.0×ULN for those with liver tumor infiltration).
  • Total bilirubin ≤2.0×ULN.
  • Oxygen saturation >92% without supplemental oxygen.
  • Eligible for single or venous blood collection with no contraindications to cell collection.
  • Consent to use a reliable and effective method of contraception for 1 year after CAR-T cell infusion (excluding the rhythm method).
  • The participant or their authorized guardian agrees to participate in the clinical trial and signs the informed consent form (ICF), indicating an understanding of the trial's purpose and procedures.

Exclusion Criteria:

  • Clinical symptoms of CNS metastasis or meningeal metastasis at screening, or other evidence suggesting that CNS metastasis or meningeal metastasis is uncontrolled, as determined by the investigator.
  • Participation in other clinical trials within 4 weeks prior to screening.
  • Receipt of a live attenuated vaccine within 4 weeks prior to screening.
  • Receipt of chemotherapy, targeted therapy, or other experimental drugs within 14 days or at least 5 half-lives (whichever is shorter) prior to screening.
  • Active or uncontrolled infection requiring systemic treatment.
  • Tumor compression of the trachea or major blood vessels, with significant risk as assessed by the investigator.
  • History of any of the following cardiac diseases:
  • New York Heart Association (NYHA) Class III or IV congestive heart failure.
  • Myocardial infarction or coronary artery bypass grafting (CABG) within 6 months prior to screening.
  • Clinically significant ventricular arrhythmias or unexplained syncope (except those caused by vasovagal or dehydration).
  • History of severe non-ischemic cardiomyopathy.
  • Active autoimmune disease or other conditions requiring long-term immunosuppressive therapy.
  • History of or concurrent untreated malignancies within 3 years, except for basal cell carcinoma or in situ cervical cancer.
  • Positive for HBsAg or HBcAb with HBV DNA levels above the normal range, HCV antibody positive with HCV RNA levels above the normal range, HIV antibody positive, or positive for syphilis.
  • Pregnant or breastfeeding women.
  • Any other condition that the investigator deems unsuitable for participation in the study.

Quoted from ClinicalTrials.gov, NCT07250386, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07250386, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07250386